Effect of LHRH agonist (buserelin) on pulsatile secretion of LHRH and LH

other public-domain-us
View on PubMed

Abstract

The LHRH agonist buserelin was administered intranasally to eight patients with endometriosis in doses of 300, 600 or 900 micrograms/day for six months. In all patients buserelin clearly suppressed ovulation. In the patients treated with 900 micrograms/day, estradiol levels declined to less than 30pg/ml, and LH release in response to LHRH testing decreased markedly after 2 months of treatment. A mild decrease in LH release was noted in the premarin test at the end of the treatment. At the end of buserelin treatment baseline levels of plasma LHRH, LHRH pulse amplitude and frequency were not lowered. However, baseline levels of plasma LH and LH pulse amplitude decreased. These results indicate that buserelin may act to decrease pituitary response to LHRH.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Buserelin Endometriosis Gonadotropin-Releasing Hormone Luteinizing Hormone Pelvic Neoplasms Secretory Rate Adult Buserelin Endometriosis Endometriosis Estradiol Estradiol Female Gonadotropin-Releasing Hormone Humans Luteinizing Hormone Ovulation Ovulation Pelvic Neoplasms Pelvic Neoplasms

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
pubmed
last seen: 2026-05-13T22:09:20.810540+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine